Compare · RPID vs RVTY
RPID vs RVTY
Side-by-side comparison of Rapid Micro Biosystems Inc. (RPID) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RPID and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 407.3x RPID ($42.4M).
- RVTY has been more active in the news (7 items in the past 4 weeks vs 1 for RPID).
- RVTY has more recent analyst coverage (23 ratings vs 11 for RPID).
- Company
- Rapid Micro Biosystems Inc.
- Revvity Inc.
- Price
- -
- -
- Market cap
- $42.4M
- $17.26B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 7
- Recent ratings
- 11
- 23
Latest RPID
- Roth Capital initiated coverage on Rapid Micro Biosystems with a new price target
- Rapid Micro Biosystems to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Rapid Micro Biosystems Inc.
- Rapid Micro Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
- Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Kollender Richard S exercised 3,508 shares at a strike of $0.75, increasing direct ownership by 3% to 133,826 units (SEC Form 4)
- PRESIDENT AND CEO Spignesi Robert G. Jr. exercised 1,402 shares at a strike of $0.75, increasing direct ownership by 0.12% to 1,191,973 units (SEC Form 4)
- Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
- Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery